Providing Appropriate Risk Information on Genome Editing for Patients.
Trends in biotechnology, 34(2): 86-90 PMID 26802361 DOI 10.1016/j.tibtech.2015.12.002
Abstract
Genome editing, represented by CRISPR/Cas9, facilitates somatic and germline gene modifications in many species, including humans. However, one of key issues, off-target mutation deserves special consideration prior to clinical applications. We herein discuss the importance of risk information on genome editing for obtaining legitimate patient consent and social acceptance.